Shepherd Investments

Shepherd is a mission-driven biotechnology company dedicated to developing treatments for the thousands of rare cancers that currently lack effective therapies. The company utilizes its proprietary DELPHI platform, a sophisticated machine learning and data integration engine, to identify and prioritize therapeutic opportunities across hundreds of rare cancer indications. By combining advanced computational biology with a focused drug development pipeline, Shepherd aims to bridge the gap between scientific discovery and patient access for underserved populations. Their lead program, SL-1001, is a first-in-class small molecule currently being evaluated in clinical trials for rare oncology indications. Through its unique structure as a social enterprise, Shepherd integrates drug development with advocacy and data sharing to transform the landscape of rare cancer care.